DEF 14A: Waters Corporation Seeks Shareholder Approval for Officer Exculpation and Reviews Executive Compensation in Proxy Statement

Waters Corporation's proxy statement outlines proposals for shareholder voting, including officer exculpation and executive compensation, while reviewing the company's performance and governance.

Summary

• Waters Corporation has released its proxy statement for the 2024 Annual Meeting of Shareholders, detailing proposals for shareholder voting.
• Key proposals include the election of directors, ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm, a non-binding vote on executive compensation, and an amendment to the company's certificate of incorporation to provide for exculpation of certain officers.
• The proxy statement reviews the company's performance in 2023, noting a revenue decline of 0.5% and 2% on a GAAP basis and adjusted non-GAAP organic constant currency basis, respectively, and an adjusted operating margin of 30.9%.
• It also highlights the company's commitment to sustainable growth and corporate governance, including board diversity and risk management practices.
• The document provides detailed information on executive and director compensation, including base salaries, annual incentives, and long-term equity awards.
• The proxy statement also includes information on security ownership, related party transactions, and procedures for shareholder proposals and director nominations for the 2025 annual meeting.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While it highlights positive aspects like strong operational results and board recognition, it also acknowledges market headwinds and a decline in revenue growth. The overall tone is cautiously optimistic.

Positives

• Waters shareholders experienced above-average total shareholder returns, outpacing the peer average.
• The company received another top score on the Human Rights Campaign Corporate Equality Index and earned a spot on the Dow Jones Sustainability Index.
• The Board was named 2024 Public Company Board of the Year by the National Association of Corporate Directors (NACD) New England Chapter.
• The company has a strong focus on execution, resulting in organic constant currency sales growth across most major regions outside of China.
• The company has a highly disciplined and balanced capital deployment strategy to maximize value to shareholders.
• The company has a proxy access bylaw provision that allows eligible shareholders to nominate director candidates.
• The company has robust stock ownership requirements for its directors and executive officers.

Negatives

• Waters revenue growth declined 0.5% and 2% on an organic constant currency basis in 2023.
• The company experienced diminished Biotech funding, slowed capital spending, increased geopolitical tensions, and a weakened economy in China.
• In 2023, the company's named executive officers did not receive payouts under the AIP based on corporate performance metrics not being achieved.
• Waters stock experienced a 4% decline in total shareholder return in 2023.

Risks

• The company faces market headwinds, including diminished Biotech funding, slowed capital spending, increased geopolitical tensions, and a weakened economy in China.
• The company's future results may differ significantly from forward-looking statements due to various factors, including those discussed in the company's Annual Report on Form 10-K.
• The company's compensation plans and practices could promote unnecessary risk-taking, although policies are in place to mitigate such risks.
• The company faces cybersecurity risks, which are overseen by the Audit & Finance Committee.

Future Outlook

The company anticipates significant opportunities for growth as it continues to accelerate the benefits of pioneering science.

Management Comments

• Despite some significant market headwinds, we are pleased with the progress we made in 2023.
• We delivered strong operational results, successfully completed the acquisition of Wyatt Technology LLC and expanded our work in high-growth adjacent markets.
• We focused on strong operational excellence to finish 2023 with a solid performance despite diminished Biotech funding, slowed capital spending, increased geopolitical tensions, and a weakened economy in China.
• As a result of our transformation over the past few years, we have made tremendous progress strengthening execution, revitalizing innovation, and executing our long-term strategy.

Industry Context

The document notes broad market weakness, particularly in China, and constrained customer capital expenditure for instruments globally, reflecting challenges faced by companies in the analytical instrument industry.

Comparison to Industry Standards

• Waters shareholders experienced above-average total shareholder returns, outpacing the peer average.
• The company's peer group includes Agilent, IDEXX Laboratories, Avantor, Illumina, Bio-Rad Laboratories, Mettler-Toledo, Bio-Techne, Perkin Elmer, Catalent, ResMed, Charles River Laboratories, STERIS, Cooper Companies, Teleflex, Edwards Lifesciences, and West Pharmaceutical.
• The median revenue for the peer group for the four quarters ended prior to September 2022 was $3.9 billion and the median market capitalization for the peer group as of September 2022 was $16.1 billion.

Corporate Governance

Related Party Transactions

• Ordinary course business transactions conducted on an arms length basis with Galderma S.A. (of which Dr. Flemming Ornskov is Chief Executive Officer), and Avient Corp. (of which Mr. Fearon is an independent director but not an employee) are deemed to be pre-approved or ratified by the Board.

Stakeholder Impact

• The company's performance and governance practices impact shareholders, employees, customers, and other stakeholders.
• The company is committed to delivering profitable and sustainable growth and deeply values continued input from stakeholders.
• The company's ESG policies and practices are overseen by the Nominating and Corporate Governance Committee, which reports to the Board at least annually.

Next Steps

• Shareholders are urged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Shareholders on May 23, 2024.
• The Board will consider the outcome of the Say-on-Pay vote in establishing and evaluating the company's executive compensation program.

Key Dates

Keywords

executive compensation, corporate governance, proxy statement, annual meeting, officer exculpation, financial performance, board of directors, shareholder value, risk management, sustainability